San Donato Hospital
| Italia | Turchia | Austria | |
| Trapianto di midollo osseo allogenico da donatore non correlato | da $150,000 | da $80,000 | da $180,000 |
| Trapianto di midollo osseo allogenico da donatore consanguineo | da $120,000 | da $65,000 | da $150,000 |
| Trapianto di midollo osseo | da $95,000 | da $36,000 | da $140,000 |
| Trapianto autologo di midollo osseo | da $90,000 | da $31,500 | da $50,000 |
| Radioterapia per il cancro colorettale | da $7,000 | da $7,000 | da $12,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Linfoma non-Hodgkin. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Linfoma non-Hodgkin e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Linfoma non-Hodgkin.
Direttore dell'Unità Linfomi presso il San Raffaele – il Dr. Ferreri ha fondato la Fondazione Italiana Linfomi per avanzare il trattamento dei linfomi.
Responsabile di Ematologia e Trapianto di Midollo Osseo presso il San Raffaele – il Professor Ciceri coordina sperimentazioni cliniche di terapia cellulare e genica per i tumori del sangue.
Italy recognized centers for Non-Hodgkin lymphoma therapy are specialized Scientific Institutes for Research and Healthcare (IRCCS). These government-accredited hubs integrate academic research with clinical hematology. Milan and Rome lead the country in precision medicine, bone marrow transplantation, and personalized immunotherapies.
Bookimed Expert Insight: Milan serves as Italy primary destination for lymphoma because its major centers operate as a unified network. San Raffaele alone performs 52,000+ operations annually across all specialties. This massive volume allows Dr. Fabio Ciceri and other specialists to manage rare subtypes that smaller regional hospitals rarely see.
Patient Consensus: Patients note that getting a second opinion in Milan or Rome often leads to updated staging and refined treatment plans. They emphasize choosing centers with dedicated lymphoma teams where pathology reviews are handled by hematology specialists.
Professor Andres Jose Maria Ferreri and Professor Fabio Ciceri at San Raffaele are the primary leaders in Italian Non-Hodgkin lymphoma care. They focus on advanced chemoimmunotherapy and bone marrow transplantation. These experts collaborate with the Italian Lymphoma Foundation to standardize national clinical protocols and research.
Bookimed Expert Insight: Italian lymphoma care is highly concentrated in Milan at San Raffaele and San Donato. San Raffaele performs over 52,000 operations yearly and pioneered the world first stem cell therapy. Patients benefit from institutional research rather than just individual doctor fame. This research focus often grants earlier access to trial-stage treatments for complex cases.
Patient Consensus: Patients note that subtype confirmation is the most critical step for success. They recommend bringing original pathology slides to major academic centers for a second opinion.
Lymphoma research in Italy is coordinated by the Italian Lymphoma Foundation, involving 150 specialized centers. This national network includes research institutes, universities, and hospitals. It standardizes clinical trials and diagnostic data. A centralized laboratory network ensures reproducible results for minimal residual disease monitoring.
Bookimed Expert Insight: Leading Italian hematologists often hold dual roles as both clinical directors and founders of research foundations. Dr. Andres Jose Maria Ferreri at San Raffaele was a founder of the Italian Lymphoma Foundation. This direct link between top surgeons and the national research body means patients at these centers often gain earlier access to emerging protocols before they reach smaller regional hospitals.
Patient Consensus: Patients note that research opportunities are usually referral-based rather than found through public registries. They emphasize that consulting at a large academic center in northern cities like Milan often provides more options for specialized clinical trials.
CAR T-cell therapy is available in Italy for treating relapsed or refractory non-Hodgkin lymphoma. The Italian Medicines Agency (AIFA) regulates these advanced treatments. Prominent centers in Milan and Rome provide EMA-approved therapies. These include Kymriah and Yescarta for specific hematological malignancies.
Bookimed Expert Insight: San Raffaele maintains high ratings and serves over 300,000 patients yearly. Data shows their hematology department acts as a core research hub. This attracts international patients seeking specialists like the founder of the Italian Lymphoma Foundation. Choosing such large academic centers ensures access to specialized monitoring after infusion.
Patient Consensus: Patients note that treatment is concentrated in major cities like Milan. They emphasize that traveling for care is common. Finding a specialist who can navigate eligibility and manufacturing timelines is essential for timely access.
Stem-cell transplant options for Non-Hodgkin lymphoma include autologous and allogeneic procedures. Autologous transplants use the patient's own cells after intensive chemotherapy. Allogeneic transplants utilize donor cells to create an immune response against cancer. Italian research hospitals specialize in these complex cellular therapies for relapsed cases.
Bookimed Expert Insight: Italian research hospitals like San Raffaele in Milan merge clinical care with advanced research. Dr. Fabio Ciceri leads one of Europe's largest transplant units. He oversees over 180 published studies on cell therapy. Patients benefit from this academic environment where specialists treat rare immune disorders alongside lymphomas. This high volume of diverse cases contributes to refined conditioning protocols.
Patient Consensus: Patients note that conditioning chemotherapy is often the most challenging phase of the process. Eligibility depends heavily on showing a positive response to salvage treatments before the transplant begins.
International patients can participate in NHL clinical trials through major Italian research hospitals. Access follows specific trial protocols and residency rules. Centers like San Raffaele in Milan conduct cell and gene therapy studies. Enrollment requires medical visa eligibility and strict adherence to long-term monitoring schedules.
Bookimed Expert Insight: Enrollment in Italian lymphoma trials often hinges on the hospital’s research status. San Raffaele and San Donato both hold IRCCS accreditation from the Italian Ministry of Health. This status means they are legally recognized for research-driven care. Choosing an IRCCS facility increases your access to phase I and II trials for rare NHL subtypes.
Patient Consensus: Patients note that the hardest part is not the nationality but the travel. Frequent follow-up scans and lab tests mean you must stay near the clinic for months.
Italian oncology institutions report efficacy rates of 70% to 80% for specific front-line chemotherapy regimens. Leading centers like San Raffaele utilize advanced protocols for Non-Hodgkin lymphoma. These treatments aim for high pathologic complete response and improved disease-free survival across various cancer subtypes.
Bookimed Expert Insight: Success in Italy is driven by high-volume research hospitals that hold IRCCS accreditation from the Ministry of Health. San Raffaele and San Donato both manage 300,000 patients yearly, which ensures deep clinical experience. Patients should look for centers like San Raffaele where the Lymphoma Unit director also leads national research foundations.
Patient Consensus: Patients note that remission outcomes depend heavily on the specific lymphoma subtype and stage. It is important to ask doctors for long-term durability results rather than short-term remission stats.